急性淋巴细胞白血病 中国就医指南

Acute Lymphoblastic Leukemia (ALL) is an aggressive hematologic malignancy characterized by the uncontrolled proliferation and accumulation of immature lymphoid progenitor cells—primarily B-cell or T-cell precursors—in the bone marrow, peripheral blood, and often extramedullary sites such as the central nervous system, lymph nodes, and testes. It arises from genetic alterations—including chromosomal translocations (e.g., ETV6-RUNX1, BCR-ABL1-like), aneuploidy, and mutations in genes regulating lymphocyte development, cell cycle control, and epigenetic modulation (e.g., IKZF1, PAX5, JAK-STAT pathway). These abnormalities disrupt normal differentiation, promote self-renewal, and confer resistance to apoptosis. ALL is the most common childhood cancer, accounting for approximately 25% of pediatric malignancies, with a peak incidence between ages 2 and 5 years. In adults, it represents only 20% of acute leukemias but carries significantly worse outcomes. Globally, age-standardized incidence rates range from 0.5–1.5 per 100,000 persons annually; in China, the estimated incidence is ~0.8 per 100,000, with higher burden among children under 15. Key risk factors include inherited syndromes (e.g., Down syndrome, Li-Fraumeni, ataxia-telangiectasia), prior chemotherapy or radiation exposure, and certain environmental triggers (e.g., high-dose ionizing radiation, possibly benzene—but evidence remains limited). While no strong association exists with lifestyle factors like diet or smoking, socioeconomic disparities influence timely diagnosis and access to care. The disease profoundly impacts quality of life: patients experience debilitating fatigue, recurrent infections due to neutropenia, bleeding tendencies from thrombocytopenia, bone pain, and fever. Intensive chemotherapy regimens cause acute toxicities—including mucositis, neurotoxicity (especially with vincristine and intrathecal methotrexate), hepatotoxicity, and immunosuppression—leading to prolonged hospitalizations, school or work interruption, psychosocial distress, anxiety, depression, and caregiver burden. Long-term survivors may face late effects such as cognitive deficits, endocrine dysfunction, cardiovascular complications, and secondary malignancies. Pediatric ALL has achieved >90% 5-year event-free survival in high-resource settings with risk-stratified, protocol-driven therapy; adult outcomes remain more modest (40–60% 5-year survival), underscoring the need for improved targeted agents and supportive infrastructure. Early referral to specialized hematology centers is critical for accurate immunophenotyping, cytogenetic/molecular profiling, minimal residual disease (MRD) monitoring, and enrollment in clinical trials.

# 急性淋巴细胞白血病（ALL）治疗方案与费用明细（血液科）

一、非手术/药物治疗方案

适用人群：初诊标准风险、中高危成人及儿童患者（含Ph⁻ ALL）

• •诱导缓解治疗（4–6周）：长春新碱+泼尼松+柔红霉素+左旋门冬酰胺酶（VDLP），含骨髓穿刺、流式检测、染色体/FISH/BCR::ABL1监测

• •巩固/强化治疗（4–6个月）：大剂量阿糖胞苷、甲氨蝶呤鞘注、环磷酰胺等

• •维持治疗（2–3年）：口服6-MP+甲氨蝶呤+定期监测

二、根治性治疗方案

适用人群：高危、复发/难治、Ph⁺、MRD持续阳性或移植候选者

• •异基因造血干细胞移植（allo-HSCT）：含供者筛选、预处理（Bu/Cy或Flu/Bu）、回输、GVHD防治及ICU监护

- 全套费用区间：38.0–65.0万元（公立三甲医院，含供者动员费、移植病房、抗感染支持）

三、特殊复杂方案

• •靶向治疗（Ph⁺ ALL）：达沙替尼/普纳替尼联合化疗，年药费12.0–36.0万元（医保谈判后自付约2.4–9.0万元）
• •CAR-T治疗（复发/难治）：CD19 CAR-T（如伊基仑赛注射液），单次费用120.0–129.0万元（含制备、回输、CRS管理）

方案快速选择指南

• •预算≤20万：首选规范化化疗（标准风险）
• •预算30–70万+高危因素：优先allo-HSCT
• •复发难治且经济可承受：CAR-T为一线挽救选择
• •Ph⁺ ALL：靶向药+化疗序贯移植为最优路径